Federated Hermes Reduces $12M in Centessa Pharmaceuticals plc ($CNTA)
Federated Hermes cut its Centessa Pharmaceuticals holdings by 12.5%, as shown in its latest SEC filing.
Key Points
- Federated Hermes reduced its position in Centessa Pharmaceuticals by 292,700 shares, a 12.5% decrease, ending with 2,049,439 shares valued at $83 million.
- Centessa Pharmaceuticals, trading at $40.50, has a market cap of $6.22 billion and a forward P/E ratio of -22.46.
- Other funds like Avoro Capital Advisors and Adage Capital Partners also decreased their stakes, while Pentwater Capital Management opened a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Federated Hermes has cut its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA), trimming 292,700 shares in its latest SEC filing. This reduction represents a 12.5% decrease, leaving the fund with 2,049,439 shares valued at approximately $83 million as of the reporting period.
Federated Hermes vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Federated Hermes's Centessa Pharmaceuticals Position
Federated Hermes reduced its holdings in Centessa Pharmaceuticals by 292,700 shares, which marks a 12.5% decrease. The fund now holds 2,049,439 shares, down from 2,342,139 shares previously. The value of this position is reported at about $83 million.
Other Institutional Activity in Centessa Pharmaceuticals
Several other institutional investors also adjusted their positions in Centessa Pharmaceuticals. Avoro Capital Advisors reduced its holdings by 3,125,100 shares, ending with 11,430,455 shares worth about $454 million, a 21.5% decrease. Adage Capital Partners trimmed its stake by 2,356,731 shares, now holding 8,925,010 shares valued at $354 million, reflecting a 20.9% decrease. In contrast, Pentwater Capital Management opened a new position with 8,170,000 shares, valued at approximately $325 million.
Centessa Pharmaceuticals Stock Snapshot
As of Wednesday, shares of Centessa Pharmaceuticals traded near $40.50. The company has a market capitalization of $6.22 billion. Its forward P/E ratio is not meaningful as it is currently not profitable, with a beta of 1.121. The stock's 52-week range is between $12.39 and $40.26, with a 50-day moving average of $39.66 and a 200-day moving average of $28.96. The company maintains a strong liquidity position with a current ratio of 9.53 and a quick ratio of 9.27, alongside a debt-to-equity ratio of 24.33.
$CNTA stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Centessa Pharmaceuticals reported negative earnings per share (EPS) of -$1.78, with no net margin due to its unprofitable status. The company has a return on equity (ROE) of -57.38%. Investors can expect the next earnings report on August 11, 2026.
Insider Buying and Selling at Centessa Pharmaceuticals plc
CEO Mario Alberto Accardi sold 604 shares at an average price of $39.42 on May 1, 2026. Chief People Officer Karen Anderson sold 41,076 shares on March 26, 2026, as part of a planned transaction at $30.12, having previously bought the same amount at $8.01. Additionally, Chief Business Officer Gregory Weinhoff sold 23,998 shares on March 26, 2026, after purchasing them at $3.85.
Analysts Set New Price Targets
On April 20, 2026, Wells Fargo downgraded Centessa Pharmaceuticals to a 'hold' rating with a price target of $42.00. Earlier, on April 1, 2026, Leerink Partners also downgraded the stock to 'hold' with a $40.00 target. Wolfe Research initiated coverage with a 'buy' rating and a $40.00 target on February 24, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $44.17 based on six analyst opinions.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a biotechnology company focused on developing orexin-based neuroscience therapeutics. Headquartered in Altrincham, United Kingdom, the company is led by CEO Dr. Mario Alberto Accardi. It is involved in developing treatments for central disorders of hypersomnolence, including narcolepsy. Centessa also explores treatments for neurological and neurodegenerative disorders, neuropsychiatric disorders, and has an early-stage immuno-oncology program. Founded in 2020, it employs 129 people.
Bottom Line
Federated Hermes's reduction in Centessa Pharmaceuticals reflects its latest investment strategy as reported in the SEC filing. While Centessa's stock has shown volatility, its market cap and institutional interest suggest ongoing investor attention. Investors look to these filings for insights, though they represent past positions and may not reflect current holdings.
Get Centessa Pharmaceuticals plc alerts
New 13F filings, insider trades, and analyst moves on $CNTA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.